查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930146

全球前列腺癌疫苗市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Prostate Cancer Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 169 Pages | 商品交期: 請詢問到貨日

價格

前列腺癌疫苗市場成長因素

由於前列腺癌發病率的上升以及對基於免疫療法的先進治療方案需求的增加，全球前列腺癌疫苗市場正經歷顯著增長。前列腺癌疫苗是一種治療性疫苗，旨在透過激活患者自身的免疫系統來識別和靶向癌細胞，從而減緩疾病進展並預防復發。 這些疫苗尚未獲準用於預防，主要用於疾病晚期。

根據這份報告，全球前列腺癌疫苗市場預計到2025年將達到5.3億美元。預計到2026年，市場規模將成長至5.8億美元，到2034年將達到15.5億美元，在預測期（2026-2034年）內複合年增長率（CAGR）為12.98%。北美在2025年佔市場主導地位，市佔率高達79.56%。這主要得益於該地區較高的疾病盛行率、完善的醫療基礎設施以及免疫療法的早期應用。

全球前列腺癌病例的不斷增加持續推動著對新療法的需求。傳統的療法，例如荷爾蒙療法和化療，其長期療效往往較低，尤其是在去勢抵抗性前列腺癌等晚期階段，因此需要創新的疫苗療法。

市場驅動因素

市場成長的主要驅動因素是荷爾蒙療法（包括雄性激素剝奪療法 (ADT)）抗藥性的增加。 ADT 最初透過降低睪固酮水平來抑制腫瘤生長，但許多患者最終由於基因突變和適應性癌症路徑而產生抗藥性。這種抗藥性降低了治療效果並促進了疾病進展，從而催生了對替代療法（例如前列腺癌疫苗）的需求。

此外，全球前列腺癌負擔的加重擴大了符合條件的患者群體。臨床醫生和患者對免疫療法優勢（例如標靶性、低毒性和與聯合療法的兼容性）的認識不斷提高，進一步推動了市場成長。

市場限制因子

限制市場擴張的主要因素之一是目前已獲批准的疫苗 PROVENGE（sipoleucel-T）的給藥過程冗長而複雜。 這種療法需要進行白血球分離術、密集的細胞處理和回輸，促使多個臨床步驟，耗時數天。這一耗時的過程增加了物流複雜性、治療成本和患者負擔，阻礙了其廣泛應用。

市場挑戰

市場面臨複雜的監管要求和較高的臨床試驗失敗率等挑戰。個人化癌症疫苗需要嚴格的處理、儲存和運輸條件以維持細胞完整性，這促使營運成本增加。此外，嚴格的監管審查往往會延遲審批。

臨床試驗失敗也是一項重大挑戰。多種在研疫苗未能證明其足夠的療效，促使經濟損失和創新進程的延遲。這些因素共同作用，減緩了產品開發和市場滲透。

市場機會

由於已獲批准的疫苗供應有限以及人們對免疫療法研究的興趣日益濃厚，前列腺癌疫苗市場展現出強勁的增長機會。 未被滿足的需求正推動製藥和生技公司投資研發新的候選疫苗，特別是針對早期和局部前列腺癌的疫苗。

後期臨床試驗的正面結果和研發投入的增加正在擴大研發管線。預計新型病毒免疫療法和聯合治療策略將在預測期內開闢新的成長途徑。

市場趨勢

影響市場的關鍵趨勢是基於DNA的前列腺癌疫苗的進步。這些疫苗利用腫瘤特異性抗原和腫瘤相關抗原來刺激強烈的細胞免疫反應。 DNA疫苗平台能夠實現多抗原靶向，從而提高免疫活化和治療效果。

對個人化醫療和聯合免疫療法的日益關注正在推動進一步的創新。將基於DNA的疫苗與免疫檢查點抑制劑和荷爾蒙療法相結合正在臨床研究中受到越來越多的關注。

市場區隔分析

依產品劃分，市場分為 PROVENGE（Sipulesel-T）及其他產品。 PROVENGE 產品佔市場主導地位，因為它是唯一獲得 FDA 批准的前列腺癌疫苗，其臨床療效已得到證實，並且對個性化免疫療法的需求日益增長。

依最終用戶劃分，市場分為醫院、專科診所和其他機構。醫院憑藉其先進的基礎設施、技術精湛的專業人員以及進行複雜免疫療法的能力，佔最大的市場佔有率。由於標靶腫瘤服務的擴展，專科診所預計將保持穩定成長。

區域展望

預計北美將引領攝護腺癌疫苗市場，2025年市場規模將達4.2億美元，2026年將成長至4.6億美元。該地區受益於攝護腺癌高發生率、有利的醫療保險政策以及輸液中心的廣泛應用。歐洲將佔第二大市場佔有率，這主要得益於公眾意識的提高和早期診斷措施的進展。亞太地區預計將以顯著的複合年增長率成長，這主要得益於疾病盛行率的上升和癌症治療設施的擴建。同時，拉丁美洲以及中東和非洲地區的成長速度將較為緩慢，這主要是由於治療費用高昂和公眾意識不足。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家和地區的攝護腺癌盛行率（2025 年）
  • 主要公司的產品線分析
  • 市場技術進步
  • 主要公司的新產品發布
  • 關鍵產業趨勢：併購、業務合作等

第五章 全球前列腺癌疫苗市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依產品分類
    • PROVENGE（Sipoleucel-T）
    • 其他
  • 市場分析、洞察與預測：依最終用戶分類
    • 醫院
    • 專科診所
    • 其他
  • 市場分析、洞察與預測：依地區分類
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美前列腺癌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家分類
    • 美國州/省
    • 加拿大

第七章 歐洲前列腺癌疫苗市場分析：洞察與預測（2021-2034）

  • 各國
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲各國

第八章 亞太地區前列腺癌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 其他亞太地區國家

第九章 拉丁美洲前列腺癌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第十章：中東和非洲前列腺癌疫苗市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會
    • 南非
    • 其他中東和非洲國家

第十一章：競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
    • Dendreon Pharmaceuticals LLC.
    • Barinthus Biotherapeutics
    • Candel Therapeutics, Inc.
    • BioNTech
    • Madison Vaccines, Inc.
Product Code: FBI113610

Growth Factors of prostate cancer vaccines Market

The global prostate cancer vaccines market is witnessing notable growth, driven by the rising prevalence of prostate cancer and increasing demand for advanced immunotherapy-based treatment options. Prostate cancer vaccines are therapeutic vaccines designed to activate the patient's immune system to recognize and target cancer cells, thereby delaying disease progression or controlling recurrent disease. These vaccines are not approved for preventive use and are primarily utilized in advanced disease stages.

According to the report, the global prostate cancer vaccines market was valued at USD 0.53 billion in 2025. The market is projected to grow to USD 0.58 billion in 2026 and further reach USD 1.55 billion by 2034, registering a CAGR of 12.98% during the forecast period (2026-2034). North America dominated the market in 2025, accounting for a 79.56% market share, supported by high disease prevalence, strong healthcare infrastructure, and early adoption of immunotherapy.

The growing number of prostate cancer cases worldwide continues to fuel demand for novel treatment approaches. Conventional therapies such as hormone therapy and chemotherapy often show reduced long-term effectiveness, particularly in advanced stages such as castration-resistant prostate cancer, thereby increasing the need for innovative vaccine-based therapies.

Market Drivers

A key driver of market growth is the increasing resistance to hormonal therapies, including androgen deprivation therapy (ADT). While ADT initially reduces tumor growth by lowering testosterone levels, many patients eventually develop resistance due to genetic mutations and adaptive cancer pathways. This resistance reduces treatment efficacy and increases disease progression, creating demand for alternative therapies such as prostate cancer vaccines.

Additionally, the growing global burden of prostate cancer is expanding the eligible patient population. Rising awareness among clinicians and patients regarding immunotherapy benefits-such as targeted action, lower toxicity, and compatibility with combination therapies-further supports market growth.

Market Restraints

One of the major restraints limiting market expansion is the lengthy and complex administration process of the currently approved vaccine, PROVENGE (Sipuleucel-T). The therapy requires leukapheresis, centralized cell processing, and reinfusion, spanning several days and multiple clinical steps. This time-intensive process increases logistical complexity, treatment costs, and patient burden, thereby restricting wider adoption.

Market Challenges

The market faces challenges related to complex regulatory requirements and high clinical trial failure rates. Personalized cancer vaccines require stringent handling, storage, and transportation conditions to maintain cellular integrity, leading to higher operational costs. In addition, strict regulatory scrutiny often delays approvals.

Clinical trial failures also pose a significant challenge. Several investigational vaccines have failed to demonstrate sufficient efficacy, resulting in financial losses and delayed innovation. These factors collectively slow product development and market penetration.

Market Opportunities

The prostate cancer vaccines market presents strong growth opportunities due to the limited availability of approved vaccines and the rising interest in immunotherapy research. The unmet clinical need has encouraged pharmaceutical and biotechnology companies to invest in developing new vaccine candidates, particularly for early-stage and localized prostate cancer.

Positive outcomes from late-stage clinical trials and increasing R&D investments are expanding the development pipeline. Novel viral immunotherapies and combination treatment strategies are expected to create new growth avenues over the forecast period.

Market Trends

A significant trend shaping the market is the advancement of DNA-based prostate cancer vaccines. These vaccines use tumor-specific and tumor-associated antigens to stimulate strong cellular immune responses. DNA vaccine platforms allow for multi-antigen targeting, improving immune activation and therapeutic effectiveness.

Increasing focus on personalized medicine and combination immunotherapy approaches is further accelerating innovation. DNA-based vaccines combined with immune checkpoint inhibitors and hormone therapy are gaining traction in clinical research.

Segmentation Analysis

By product, the market is divided into PROVENGE (Sipuleucel-T) and others. The PROVENGE segment dominates the market due to its status as the only FDA-approved prostate cancer vaccine, established clinical efficacy, and rising preference for personalized immunotherapy.

Based on end user, the market is segmented into hospitals, specialty clinics, and others. Hospitals hold the largest market share, owing to their advanced infrastructure, skilled professionals, and ability to administer complex immunotherapy procedures. Specialty clinics are expected to grow steadily due to the expansion of targeted oncology services.

Regional Outlook

North America led the prostate cancer vaccines market in 2025, with a market value of USD 0.42 billion, increasing to USD 0.46 billion in 2026. The region benefits from high prostate cancer incidence, favorable reimbursement policies, and widespread availability of infusion centers. Europe holds the second-largest share due to rising awareness and early diagnostic initiatives. The Asia Pacific region is expected to grow at a significant CAGR, driven by increasing disease prevalence and expansion of cancer care facilities. Latin America and the Middle East & Africa show slower growth due to high treatment costs and limited awareness.

Competitive Landscape

The market is highly consolidated, with Dendreon Pharmaceuticals LLC. holding a dominant position due to PROVENGE. Other players such as Barinthus Biotherapeutics, Candel Therapeutics, BioNTech, and Madison Vaccines are actively engaged in clinical research and product development. Strategic investments, clinical trial advancements, and innovation in vaccine platforms are expected to shape the competitive landscape during the forecast period.

Conclusion

The prostate cancer vaccines market is poised for strong growth, driven by the rising global burden of prostate cancer and the increasing shift toward immunotherapy-based treatment approaches. Valued at USD 0.53 billion in 2025, the market is projected to grow to USD 0.58 billion in 2026 and further reach USD 1.55 billion by 2034, registering a robust CAGR of 12.98% during 2026-2034. The growing limitations of conventional hormone therapies, particularly in advanced and castration-resistant prostate cancer, continue to create demand for innovative vaccine-based solutions.

Despite challenges such as complex administration procedures, high treatment costs, and stringent regulatory requirements, ongoing advancements in DNA-based vaccines, personalized immunotherapy, and combination treatment strategies are expected to drive future market expansion. The strong dominance of North America, supported by early adoption of immunotherapy and favorable reimbursement policies, further strengthens the market outlook. Overall, continued R&D investments, expanding clinical pipelines, and rising awareness of therapeutic cancer vaccines are expected to support sustained growth of the prostate cancer vaccines market through 2034.

Segmentation By Product

  • PROVENGE (sipuleucel-T)
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Geography

  • North America (By Product, End User, and Country )
    • U.S.
    • Canada
  • Europe (By Product, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Product, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Product, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Technological Advancements in Market
  • 4.4. New Product Launches, by Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. PROVENGE (sipoleucel-T)
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By End User
    • 5.2.1. Hospitals
    • 5.2.2. Specialty Clinics
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. PROVENGE (sipoleucel-T)
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By End User
    • 6.2.1. Hospitals
    • 6.2.2. Specialty Clinics
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. PROVENGE (sipoleucel-T)
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By End User
    • 7.2.1. Hospitals
    • 7.2.2. Specialty Clinics
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.3.1. Germany
    • 7.3.2. U.K.
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Rest of Europe

8. Asia Pacific Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. PROVENGE (sipoleucel-T)
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By End User
    • 8.2.1. Hospitals
    • 8.2.2. Specialty Clinics
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Rest of Asia Pacific

9. Latin America Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. PROVENGE (sipoleucel-T)
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By End User
    • 9.2.1. Hospitals
    • 9.2.2. Specialty Clinics
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. PROVENGE (sipoleucel-T)
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By End User
    • 10.2.1. Hospitals
    • 10.2.2. Specialty Clinics
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Dendreon Pharmaceuticals LLC.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. Financials (Based on Availability)
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. SWOT,Etc.
    • 11.2.2. Barinthus Biotherapeutics
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. Financials (Based on Availability)
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. SWOT,Etc
    • 11.2.3. Candel Therapeutics, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. Financials (Based on Availability)
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. SWOT,Etc
    • 11.2.4. BioNTech
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. Financials (Based on Availability)
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. SWOT,Etc
    • 11.2.5. Madison Vaccines, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. Financials (Based on Availability)
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. SWOT,Etc

List of Tables

  • Table 1: Global Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 2: Global Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 3: Global Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 4: North America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 5: North America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 6: North America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 7: Europe Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 8: Europe Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 9: Europe Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 10: Asia Pacific Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 11: Asia Pacific Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 12: Asia Pacific Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Latin America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 14: Latin America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 15: Latin America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Middle East & Africa Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 17: Middle East & Africa Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 18: Middle East & Africa Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Prostate Cancer Vaccines Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 2: Global Prostate Cancer Vaccines Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Prostate Cancer Vaccines Market Value Share (%), by End User, 2025 & 2034
  • Figure 4: Global Prostate Cancer Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 5: North America Prostate Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 6: North America Prostate Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 7: North America Prostate Cancer Vaccines Market Value (USD million), by End User, 2025 & 2034
  • Figure 8: North America Prostate Cancer Vaccines Market Value Share (%), by End User, 2025
  • Figure 9: North America Prostate Cancer Vaccines Market Value (USD million), By Country, 2025 & 2034
  • Figure 10: North America Prostate Cancer Vaccines Market Value Share (%), By Country, 2025
  • Figure 11: Europe Prostate Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 12: Europe Prostate Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 13: Europe Prostate Cancer Vaccines Market Value (USD million), by End User, 2025 & 2034
  • Figure 14: Europe Prostate Cancer Vaccines Market Value Share (%), by End User, 2025
  • Figure 15: Europe Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 16: Europe Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 17: Asia Pacific Prostate Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 18: Asia Pacific Prostate Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 19: Asia Pacific Prostate Cancer Vaccines Market Value (USD million), by End User, 2025 & 2034
  • Figure 20: Asia Pacific Prostate Cancer Vaccines Market Value Share (%), by End User, 2025
  • Figure 21: Asia Pacific Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 23: Latin America Prostate Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 24: Latin America Prostate Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 25: Latin America Prostate Cancer Vaccines Market Value (USD million), by End User, 2025 & 2034
  • Figure 26: Latin America Prostate Cancer Vaccines Market Value Share (%), by End User, 2025
  • Figure 27: Latin America Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 28: Latin America Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 29: Middle East & Africa Prostate Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 30: Middle East & Africa Prostate Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 31: Middle East & Africa Prostate Cancer Vaccines Market Value (USD million), by End User, 2025 & 2034
  • Figure 32: Middle East & Africa Prostate Cancer Vaccines Market Value Share (%), by End User, 2025
  • Figure 33: Middle East & Africa Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 34: Middle East & Africa Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 35: Global Prostate Cancer Vaccines Market Share (%), By Company, 2025